ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  05/23 04:00:00 pm EDT
7.460 USD   -0.27%
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08:00 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ALLOGENE THERAPEUTICS, INC.
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
CI
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/05Raymond James Adjusts Allogene Therapeutics' Price Target to $13 from $36, Keeps Outper..
MT
05/04TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04Allogene Therapeutics Reports First Quarter 2022 Financial Results
GL
05/04Allogene Therapeutics Reports First Quarter 2022 Financial Results
AQ
05/04Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
04/28Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
AQ
04/28Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
GL
04/28Allogene Therapeutics, Inc. Appoints Susan Lundeen as Chief People Officer, Effective M..
CI
04/27Allogene Secures FDA's Orphan Drug Designation for Multiple Myeloma Drug Candidate
MT
More most relevant news
All news about ALLOGENE THERAPEUTICS, INC.
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
CI
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/05Raymond James Adjusts Allogene Therapeutics' Price Target to $13 from $36, Keeps Outper..
MT
05/04TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/04ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
News in other languages on ALLOGENE THERAPEUTICS, INC.
05/04Allogene Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
04/28Allogene Therapeutics, Inc. nomme Susan Lundeen au poste de Chief People Officer, à com..
04/27Allogene obtient de la FDA la désignation de médicament orphelin pour son candidat médi..
04/14Allogene Therapeutics dévoile Cell Forge 1, une installation de fabrication de concepti..
04/13Selon Allogene Therapeutics, les données précliniques montrent que l'ALLO-316 a le pote..
03/10Allogene Therapeutics reçoit la désignation Fast-Track de la FDA pour l'ALLO-316 dans l..
03/10Allogene Therapeutics, Inc. reçoit la désignation Fast Track de la FDA pour son premier..
02/23Allogene Therapeutics, Inc. publie ses résultats pour l'année complète se terminant le ..
02/23Allogene Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 3..
01/14ACHAT D'INITIÉS : Allogene Therapeutics
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
05/05Raymond James Adjusts Allogene Therapeutics' Price Target to $13 from $36, Keeps Outper..
MT
02/28B. Riley Lowers Allogene Therapeutics' PT to $21 from $30 on Heels of Regulatory Requir..
MT
01/03Guggenheim Adjusts Price Target for Allogene Therapeutics to $35 From $40, Maintains Bu..
MT
2021RBC Cuts Price Target on Allogene Therapeutics to $35 From $45 Amid 'Mixed' Data, Keeps..
MT
2021ALLOGENE THERAPEUTICS : Cowen Starts Allogene Therapeutics at Outperform
MT
More recommendations
Press releases
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/04ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
More press releases
Upcoming event on ALLOGENE THERAPEUTICS, INC.